A promising treatment, retatrutide, is creating considerable anticipation within the Oz weight management community. Developed by Lilly , this dual GIP and GLP-1 receptor appears to provide more impressive outcomes than existing therapies. Early clinical trials have shown noteworthy reductions in body weight , indicating a for a different method… Read More